Since differing entities of our cohort might lead to heterogeneous results, further longitudinal investigations, such as using dopamine transporter or cardiac imaging to discriminate between risks of conversion to PD vs. MSA, may also help to clarify this question. This evidence concerns the gene SLC6A3 and multiple system atrophy.